Sign in
CompletedNo phase

Epidemiological Studies and Risk Factor Analysis of GERD in Xiamen City

Key facts

Who runs it
Zhongshan Hospital (Xiamen), Fudan University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
1,625 people enrolled
Started
1 Aug 2024
Ended
31 Oct 2025
Type of study
Observational
Record updated
13 March 2026

Who can take part

Age
16 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • All patients had experienced typical reflux symptoms, i.e., mild heartburn and/or regurgitation symptoms, for at least 2 days per week or moderate/severe reflux symptoms for more than 1 day per week during the previous 3 months and had upper endoscopy examinations in the previous month
  • Cooperate with the questionnaire survey
  • Volunteer and sign the informed consent form
  • Permanent residents in Xiamen

Who cannot take part

  • Malignant tumor
  • Failing to cooperate with the investigation because of the factors such as education level and language intelligence disorder, etc
  • Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine and mental system diseases
  • Partial or total gastrectomy
  • Patients with mental retardation, etc

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gastroesophageal Reflux Disease (GERD) is a condition characterized by the reflux of gastric and duodenal contents into the esophagus, primarily manifested by symptoms such as acid regurgitation and heartburn. GERD significantly affects patients' daily lives and health-related quality of life. Prolonged gastroesophageal reflux can lead to repeated irritation of the esophageal mucosa by gastric acid and acidic gastric contents, resulting in the replacement of normal squamous epithelium in the lower esophagus with metaplastic columnar epithelium. This pathological change, known as Barrett's Esophagus (BE), is considered a precancerous lesion for esophageal adenocarcinoma.

The group in the trial

  • Gastroesophageal Reflux Disease

    Gastroesophageal reflux disease (GERD) is a gastrointestinal motility disorder that results from the reflux of stomach contents into the esophagus or oral cavity resulting in symptoms or complications.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Epidemiological Studies and Risk Factor Analysis of Gastroesophageal Reflux Diseases in Xiamen City: a Cross-sectional Study
Record updated
13 March 2026